List of Excipients in Branded Drug NITROPRESS

Generic Drugs Containing NITROPRESS

Company	Ingredient	NDC	Excipient
Bausch Health US LLC	sodium nitroprusside	0187-4302	WATER

What are the Most Frequently-Used Excipients in NITROPRESS?

# Of NDCs	Excipient
1	WATER

Nitropres Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Nitropress is the former branded injectable formulation of sodium nitroprusside, a rapidly acting intravenous vasodilator used for immediate blood-pressure reduction and controlled hypotension during surgery. The commercial opportunity is not a conventional branded-drug relaunch. It is an injectable reformulation and supply-chain opportunity centered on ready-to-use dosing, light protection, stability, workflow safety, and shortage-resistant manufacturing.

Sodium nitroprusside has no meaningful modern composition-of-matter exclusivity. Commercial protection would need to come from formulation patents, device claims, manufacturing know-how, regulatory execution, hospital contracts, and differentiated packaging.

What is Nitropress and what formulation does it use?

Nitropress contains sodium nitroprusside, also known as sodium nitroferricyanide, for intravenous infusion. The historical product was supplied as a concentrated sterile solution requiring dilution before administration. Sodium nitroprusside is highly potent, has a rapid onset and offset, and requires continuous blood-pressure monitoring during use.[1]

Nitropress product profile

Attribute	Nitropress profile
Active ingredient	Sodium nitroprusside
Route	Intravenous infusion
Historical strength	50 mg/2 mL vial, equivalent to 25 mg/mL
Therapeutic use	Immediate reduction of blood pressure; controlled hypotension
Administration	Dilution into a compatible intravenous solution before infusion
Primary stability issue	Light sensitivity
Main toxicology issue	Cyanide and thiocyanate formation during metabolism
Regulatory category	Prescription injectable drug
Commercial status	Historical brand; generic sodium nitroprusside products remain the relevant market reference

The approved labeling for sodium nitroprusside emphasizes protection from light, controlled infusion, continuous monitoring, and dose-related cyanide toxicity.[1,2] These requirements directly determine the most attractive excipient and packaging strategies.

What excipients are used in Nitropress and generic sodium nitroprusside?

The core injectable formulation uses a simple aqueous vehicle. Public product labeling for sodium nitroprusside injection identifies water for injection as the principal inactive component, with pH adjustment as applicable to the specific manufacturer and presentation.[1,3]

Exact excipient composition should be verified against the current product-specific label because generic manufacturers may use different pH-adjusting agents, container systems, and dilution instructions. The formulation strategy is generally constrained by the following requirements:

• Sterility and parenteral safety.
• Chemical stability of sodium nitroprusside in solution.
• Low particulate burden.
• Compatibility with infusion bags, tubing, and pumps.
• Adequate pH control without introducing clinically relevant buffer load.
• Light protection through the container, overwrap, or administration set.
• Minimal excipient burden for a product used in critically ill patients.

Likely excipient functions

Formulation component	Function	Commercial relevance
Water for injection	Injectable vehicle	Standard, low differentiation
pH adjuster	Controls solution pH	Potential stability and container-compatibility variable
Optional tonicity agent	Adjusts osmolality where needed	Must be justified by stability and tolerability data
Antioxidant or chelator	Controls oxidative or metal-catalyzed degradation	High regulatory and compatibility burden
Buffer system	Controls pH drift	May improve stability but can increase precipitation or compatibility risk
Light-protective container or overwrap	Reduces photodegradation	More commercially attractive than complex excipient systems
Ready-to-use diluent	Eliminates bedside dilution	Strongest product differentiation opportunity

A low-excipient formulation is preferable. Sodium nitroprusside is administered in emergency and perioperative settings, where every added excipient creates a new burden for toxicology, compatibility, extractables and leachables, stability, and regulatory review.

What are the main formulation challenges for sodium nitroprusside?

The critical technical problem is not solubility. It is maintaining potency and controlling degradation during storage, dilution, transport, and administration.

Light sensitivity

Sodium nitroprusside is light sensitive. Product labeling requires protection from light, including protection of the prepared infusion solution.[1,2] Light exposure can reduce potency and create degradation products. A commercial formulation should therefore treat photoprotection as a system-level requirement rather than relying only on an excipient.

Potential solutions include:

1. Amber or opaque primary containers.
2. Aluminum foil or multilayer light-barrier overwraps.
3. Opaque infusion bags.
4. Light-protective administration tubing.
5. Integrated packaging instructions and visible light-exposure indicators.
6. Photostability-qualified ready-to-use bags.

Packaging claims are generally easier to defend commercially than broad claims directed only to an excipient concentration. A patent could cover the combination of sodium nitroprusside, a specified container, a light transmission threshold, and a defined storage or administration period.

pH and chemical stability

The formulation must maintain an acceptable pH over its shelf life without accelerating decomposition. A buffer may reduce pH drift, but the buffer itself can affect degradation kinetics, compatibility, and parenteral tolerability.

A development program should evaluate:

• Initial pH and pH drift.
• Assay and related substances.
• Cyanide and thiocyanate-related degradation markers.
• Color change and visible particles.
• Container closure integrity.
• Compatibility with common infusion diluents.
• Stability after dilution at refrigerated and controlled room-temperature conditions.
• Photostability under ICH conditions.
• In-use stability in the final infusion container and administration set.

A successful formulation should not be judged only by initial assay. The commercial label must support a credible in-use period that fits hospital workflows.

Cyanide toxicity

Sodium nitroprusside metabolism can produce cyanide, particularly during prolonged administration or at higher doses. The labeling contains dose and duration warnings and recommends clinical monitoring where appropriate.[1,2]

Excipient selection cannot remove the pharmacologic cyanide risk. Commercial value instead comes from reducing medication errors and improving dose control. The highest-value product concepts may pair a stable formulation with:

• Standardized concentration.
• Smart-pump library integration.
• Clear dose-volume labeling.
• Ready-to-use presentation.
• Barcoded unit-dose packaging.
• Institutional protocols for monitoring.

What formulations are protected by existing Nitropress patents?

No current, commercially important Nitropress patent estate is apparent from the historical status of the product. Nitropress is an old small-molecule injectable, and any original composition-of-matter or basic formulation protection would have expired decades ago.

The relevant intellectual-property opportunity is therefore a new formulation or delivery system, not resurrection of legacy brand exclusivity. Candidate claim categories include:

Claim category	Potential subject matter	Relative strength
Excipient composition	Sodium nitroprusside with a defined buffer, pH range, or stabilizer	Moderate if unexpected stability is demonstrated
Ready-to-use solution	Defined concentration, diluent, pH, shelf life, and light protection	Moderate to strong if clinically useful
Container system	Low-light-transmission vial, bag, overwrap, or tubing	Moderate
Administration set	Integrated light protection or dose-control system	Moderate
Manufacturing process	Controlled oxygen exposure, mixing, sterilization, or filling process	Moderate, often difficult to detect in the market
Stability method	Defined degradation limits and storage conditions	Usually narrower
Combination product	Drug, container, pump, and monitoring configuration	Potentially strong but more complex
Method of use	Reduced medication error, controlled hypotension, or specific perioperative use	Narrow and subject to prior-art risk

A formulation patent should be based on comparative data. A claim that merely substitutes one routine pH adjuster for another would face significant obviousness risk. Stronger protection would require an unexpected result, such as substantially longer in-use stability, lower photodegradation, improved compatibility with infusion devices, or an extended ready-to-use shelf life.

When does Nitropress lose exclusivity?

Nitropress has no meaningful remaining regulatory exclusivity based on the age of the product. The commercial market is governed by generic approval, manufacturing capacity, supply reliability, and hospital purchasing contracts rather than by a pending brand exclusivity period.

FDA regulatory status

FDA-approved sodium nitroprusside products are generally regulated as abbreviated new drug applications or legacy injectable products. A new commercial entrant could pursue several pathways:

Strategy	Likely pathway	Main advantage
Conventional generic concentrate	ANDA	Lower development cost if reference product and requirements are clear
Ready-to-use premix	ANDA or 505(b)(2), depending on formulation and reference relationship	Differentiated administration format
New container and light-barrier system	ANDA or 505(b)(2)	Potential stability and workflow advantages
Novel concentration	Often 505(b)(2) risk increases	May reduce dilution errors
Drug-device presentation	505(b)(2) or combination-product review	Integrated hospital workflow
New indication or clinical use	505(b)(2) with clinical support	Broader commercial positioning

The appropriate pathway depends on the proposed formulation, reference product, strength, dosage form, and extent of new clinical data. FDA’s Orange Book and Drugs@FDA records should be used to confirm current listed products, reference designations, and regulatory status.[4,5]

How many patents cover Nitropress?

The practical answer is that no active, foundational patent appears to block generic sodium nitroprusside commercialization. Patent risk is more likely to arise from later formulation, packaging, device, or manufacturing patents than from Nitropress itself.

A freedom-to-operate review should search:

• “Nitropress.”
• “Sodium nitroprusside.”
• “Sodium nitroferricyanide.”
• Ready-to-use sodium nitroprusside infusion.
• Light-protected nitroprusside formulations.
• Premixed vasodilator infusions.
• Photostable injectable cyanide-nitroprusside compositions.
• Infusion systems for controlled hypotension.
• Hospital compounding alternatives.

The review should cover U.S. patents, published applications, European filings, Japanese filings, and jurisdictions with substantial injectable-drug manufacturing capacity. Patent families should be separated from individual national filings to avoid overstating the size of the estate.

What commercial opportunities exist for Nitropress reformulation?

The strongest opportunity is a ready-to-use, light-protected sodium nitroprusside infusion supplied in a standardized hospital concentration.

Opportunity 1: Ready-to-use premix

Hospitals currently incur labor and error risk when pharmacy or nursing staff dilute concentrated injectable products. A premixed bag could reduce:

• Bedside preparation time.
• Dilution calculation errors.
• Manipulation of a light-sensitive product.
• Use of nonstandard concentrations.
• Waste from partially used vials.
• Dependence on immediate sterile compounding capacity.

The product could be supplied in several clinically relevant concentrations, but excessive SKU expansion would increase inventory complexity. A single high-volume concentration with a clear dosing chart may be more commercially attractive than a broad portfolio.

Opportunity 2: Extended in-use stability

A formulation with validated stability after dilution could support emergency departments, operating rooms, intensive-care units, and pharmacy batch preparation. Commercial value depends on the actual labeled storage period and whether the product remains stable in common diluents and containers.

An extended in-use claim is most valuable if it allows hospitals to prepare doses in advance without compromising potency or light protection.

Opportunity 3: Integrated photoprotection

Many products place responsibility for light protection on the user. A manufacturer can shift that burden into the product design through:

• Opaque bags.
• Light-resistant tubing.
• Tamper-evident overwraps.
• Color-coded labels.
• Packaging that prevents administration without the protective covering.
• Time-temperature-light indicators.

This is a practical differentiation strategy because it addresses a known label requirement without adding a pharmacologically unnecessary excipient.

Opportunity 4: Pharmacy-compounding alternative

A commercially manufactured premix could compete with hospital-compounded sodium nitroprusside. The value proposition would be strongest where institutions face:

• Sterile-compounding capacity constraints.
• Drug shortages.
• High procedural volume.
• Strict beyond-use dating controls.
• Limited after-hours pharmacy staffing.

Opportunity 5: Contract manufacturing and regional supply

Sodium nitroprusside is a niche injectable. A manufacturer may obtain better economics through contract manufacturing, dual-site production, or regional hospital agreements rather than mass-market retail distribution.

The key manufacturing requirements are sterile filling, validated light-control packaging, low-particulate production, container-closure integrity, and reliable supply of active pharmaceutical ingredient. FDA’s Drug Shortages database should be monitored because scarcity or supply disruption can materially improve the value of a differentiated presentation.[6]

Which companies are challenging or competing with Nitropress?

The competitive set is primarily composed of generic injectable manufacturers and hospital compounders, not branded innovator companies. Relevant competitors may include manufacturers marketing sodium nitroprusside injection under generic labels, depending on current FDA listings and market availability.

Competition should be assessed across five dimensions:

Dimension	Commercial question
Product format	Concentrate or ready-to-use infusion?
Packaging	Does the supplier provide integrated light protection?
Stability	What is the labeled shelf life and post-dilution period?
Supply	Is the product consistently available?
Price	Does the product displace pharmacy compounding or reduce labor cost?

A new entrant would have difficulty winning solely on active-ingredient price. The strongest differentiation would combine reliable availability with lower preparation burden and documented stability.

What patent litigation and Paragraph IV risks exist?

A legacy sodium nitroprusside product is unlikely to generate substantial current Paragraph IV litigation because the core drug and basic injectable concept are old. Litigation risk becomes more relevant if a company launches a patented ready-to-use formulation or device.

Potential disputes could involve:

• Orange Book-listed formulation patents.
• Container and packaging patents.
• Stability claims.
• Concentration and dilution methods.
• Drug-device combination claims.
• Manufacturing-process patents.
• Patent-term extension or pediatric-exclusivity questions for any newer product.

A Paragraph IV certification against a listed formulation patent could create a 30-month stay if the statutory requirements are met. The practical risk depends on whether the patent claims the product itself, the labeled method of use, or a manufacturing process that is difficult to prove from the finished product.

Settlement agreements would need review for launch dates, licenses, covenants not to sue, authorized-generic provisions, and restrictions on ready-to-use presentations. No material current settlement should be assumed without a case-specific review of FDA and court records.

How strong is the Nitropress patent estate?

The legacy Nitropress estate is weak as a barrier to entry and commercially irrelevant as a basis for sustained exclusivity. A new formulation estate could be moderate if it includes:

1. A measurable stability improvement.
2. A commercially necessary light-protection system.
3. A defined ready-to-use concentration.
4. Compatibility with standard infusion equipment.
5. Data supporting a clinically useful in-use period.
6. Claims that avoid routine formulation choices.

The estate would be stronger if claims cover both composition and presentation. A composition-only patent may be designed around by changing the buffer or stabilizer. A packaging-only patent may be vulnerable to substitution with another light-barrier material. A coordinated portfolio can cover the formulation, container, administration set, and method of use.

What generic launch scenarios exist for Nitropress?

Scenario 1: Low-cost generic concentrate

This is the lowest-risk entry strategy but offers limited differentiation. It competes primarily on price, supply, and contract coverage.

Scenario 2: Ready-to-use premix

This has higher development and validation costs but offers a clearer hospital value proposition. It can support premium pricing if it reduces pharmacy labor, waste, and medication-preparation risk.

Scenario 3: Dual-source hospital supply

A manufacturer could position the product as a shortage-resilient alternative through two manufacturing sites or an established contract-manufacturing network. Reliability may matter more than a small price discount in critical-care purchasing.

Scenario 4: Integrated drug-device system

A light-protected bag with compatible tubing and pump-library support could create higher switching costs. The regulatory pathway and procurement process would be more complex.

What is the revenue exposure and market size?

Sodium nitroprusside is a specialized injectable with a much smaller market than broad cardiovascular drugs. Revenue depends on hospital procedure volume, ICU utilization, generic competition, shortages, and whether the product is sold as a concentrate or premix.

The principal revenue pools are:

• Operating-room controlled hypotension.
• Intensive-care blood-pressure management.
• Emergency hypertensive crises.
• Cardiac and vascular procedures.
• Hospital pharmacy premix contracts.
• Public-sector and group-purchasing-organization tenders.

A realistic commercial model should not rely on high unit volume. It should model premium pricing for workflow reduction, supply reliability, and validated stability. Gross margin can be attractive if the product secures institutional contracts, but a small market and concentrated purchasing base create price pressure.

How does Nitropress compare with competing intravenous vasodilators?

Product	Main advantage	Main limitation	Excipient opportunity
Sodium nitroprusside	Very rapid, titratable blood-pressure reduction	Cyanide risk; light sensitivity; intensive monitoring	Ready-to-use, photostable premix
Nicardipine injection	Widely used titratable calcium-channel blocker	Longer operational profile; formulation compatibility issues	Premix and standardized concentration
Clevidipine emulsion	Rapid titration with short action	Lipid-emulsion handling and cost	Container stability and administration convenience
Nitroglycerin injection	Established vasodilator	Different pharmacologic profile and indications	Premix and adsorption-control packaging
Hydralazine injection	Low-cost intermittent option	Less predictable titration	Limited formulation differentiation

Sodium nitroprusside should be positioned where immediate, continuous titration is clinically valuable. It should not be marketed as a universal replacement for other intravenous antihypertensives.

Key Takeaways

• Nitropress is an older sodium nitroprusside injectable with no meaningful foundational patent barrier.
• The core formulation is a simple aqueous sterile solution; formulation complexity should be minimized.
• Light protection, dilution stability, and cyanide-risk management drive product design.
• The strongest commercial opportunity is a ready-to-use, light-protected premix with standardized concentration.
• A differentiated product could pursue an ANDA or 505(b)(2) pathway depending on formulation and presentation.
• New patent value would come from demonstrated stability, container systems, administration sets, or integrated workflow solutions.
• Generic competition is likely to focus on price and availability, while a reformulated product can compete on labor reduction and medication safety.
• The market is niche, hospital-centered, and sensitive to supply reliability.
• A credible IP portfolio should combine composition, packaging, manufacturing, and method-of-use claims.
• Paragraph IV risk is limited for the legacy product but could arise against newer formulation or device patents.

Frequently Asked Questions

Is sodium nitroprusside still commercially viable after Nitropress?

Yes, but primarily as a hospital injectable with differentiated packaging, reliable supply, or a ready-to-use presentation. A basic concentrate would face strong generic price competition.

Can a company patent a new Nitropress excipient formulation?

Yes, if the formulation produces a non-obvious and measurable technical result, such as improved photostability, longer in-use stability, or better container compatibility. Routine substitutions are vulnerable to validity challenges.

Does sodium nitroprusside require a preservative?

A preservative is generally unnecessary and may be undesirable for an intravenous product intended for controlled hospital infusion. The final requirement depends on the container, presentation, and FDA-approved formulation.

Is a ready-to-use sodium nitroprusside bag a 505(b)(2) product?

It may be eligible for an ANDA if it can meet applicable generic requirements and establish pharmaceutical equivalence. If the presentation introduces substantial formulation, stability, concentration, or clinical differences, a 505(b)(2) pathway may be more appropriate.

What is the most valuable patent claim for a sodium nitroprusside premix?

A claim covering the active ingredient, defined concentration, selected diluent, pH range, light-barrier container, and validated stability period is generally more commercially useful than a narrow claim directed only to a conventional excipient.

References

1. U.S. Food and Drug Administration. (2017). Nitropress (sodium nitroprusside) injection prescribing information.
2. U.S. National Library of Medicine. (2024). Sodium nitroprusside injection: Drug label information. DailyMed.
3. U.S. National Library of Medicine. (2024). Sodium nitroprusside injection, solution: Inactive ingredients and labeling. DailyMed.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
6. U.S. Food and Drug Administration. (2024). Drug shortages database.